Pharmacokinetics of perlolyrine in rats by stable isotope dilution in conjunction with GC-MS
Abstract
"AIM:
To determine the pharmacokinetics of perlolyrine in rats.
METHODS:
The plasma concentration and pharmacokinetic parameters of perlolyrine were determined by gas chromatography-mass spectrometry (GC-MS) with selected ion (m/z 247 and m/z 248) and [2-(15) N] perlolyrine (m/z 248) as internal standard.
RESULTS:
The concentration-time profile of perlolyrine after ig perlolyrine 2 mg.kg-1 fitted a two-compartment open model in rats. The pharmacokinetic parameters were T1/2 alpha = 0.33 h, T1/2 beta = 4.52 h, T1/2 (ka) = 0.14 h, Tmax = 0.35 h, Cmax = 18.84 micrograms/L, K12 = 0.88 h-1, K21 = 0.42 h-1, K10 = 0.32 h-1, V/F = 109.22 L.kg-1, AUC = 112.68 micrograms.h.L-1.
CONCLUSION:
The method was constant, sensitive, and accurate. It provides a useful method for the determination of pharmacokinetics of perlolyrine which are important for clinical use of perlolyrine."
Keywords:
To determine the pharmacokinetics of perlolyrine in rats.
METHODS:
The plasma concentration and pharmacokinetic parameters of perlolyrine were determined by gas chromatography-mass spectrometry (GC-MS) with selected ion (m/z 247 and m/z 248) and [2-(15) N] perlolyrine (m/z 248) as internal standard.
RESULTS:
The concentration-time profile of perlolyrine after ig perlolyrine 2 mg.kg-1 fitted a two-compartment open model in rats. The pharmacokinetic parameters were T1/2 alpha = 0.33 h, T1/2 beta = 4.52 h, T1/2 (ka) = 0.14 h, Tmax = 0.35 h, Cmax = 18.84 micrograms/L, K12 = 0.88 h-1, K21 = 0.42 h-1, K10 = 0.32 h-1, V/F = 109.22 L.kg-1, AUC = 112.68 micrograms.h.L-1.
CONCLUSION:
The method was constant, sensitive, and accurate. It provides a useful method for the determination of pharmacokinetics of perlolyrine which are important for clinical use of perlolyrine."